Biotest Aktiengesellschaft (HAM:BIO)

Market Cap	1.37B
Revenue (ttm)	635.20M
Net Income (ttm)	-24.50M
Shares Out	n/a
EPS (ttm)	-0.63
PE Ratio	n/a
Forward PE	23.09
Dividend	n/a
Ex-Dividend Date	n/a

Volume	161
Average Volume	50
Open	37.80
Previous Close	41.20
Day's Range	37.40 - 37.80
52-Week Range	35.00 - 45.60
Beta	n/a
RSI	45.62
Earnings Date	Nov 10, 2025

About HAM:BIO

Biotest Aktiengesellschaft develops, manufactures, and sells biological and biotechnological pharmaceutical products in Germany and internationally. The company specializes primarily in the therapeutic areas of clinical immunology, haematology, and intensive care medicine. Its products include Haemoctin SDH and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company also offers Cytotect CP biotest for prophylaxis of the clinical manifestation of cytomega...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1946
• Employees: 2,495
• Stock Exchange: Hamburg Stock Exchange
• Ticker Symbol: BIO

Financial Performance

In 2024, HAM:BIO's revenue was 726.20 million, an increase of 6.08% compared to the previous year's 684.60 million. Earnings were 26.40 million, a decrease of -79.21%.